» Articles » PMID: 20132098

Cellular and Molecular Biology of Neisseria Meningitidis Colonization and Invasive Disease

Overview
Journal Clin Sci (Lond)
Date 2010 Feb 6
PMID 20132098
Citations 84
Authors
Affiliations
Soon will be listed here.
Abstract

The human species is the only natural host of Neisseria meningitidis, an important cause of bacterial meningitis globally, and, despite its association with devastating diseases, N. meningitidis is a commensal organism found frequently in the respiratory tract of healthy individuals. To date, antibiotic resistance is relatively uncommon in N. meningitidis isolates but, due to the rapid onset of disease in susceptible hosts, the mortality rate remains approx. 10%. Additionally, patients who survive meningococcal disease often endure numerous debilitating sequelae. N. meningitidis strains are classified primarily into serogroups based on the type of polysaccharide capsule expressed. In total, 13 serogroups have been described; however, the majority of disease is caused by strains belonging to one of only five serogroups. Although vaccines have been developed against some of these, a universal meningococcal vaccine remains a challenge due to successful immune evasion strategies of the organism, including mimicry of host structures as well as frequent antigenic variation. N. meningitidis express a range of virulence factors including capsular polysaccharide, lipopolysaccharide and a number of surface-expressed adhesive proteins. Variation of these surface structures is necessary for meningococci to evade killing by host defence mechanisms. Nonetheless, adhesion to host cells and tissues needs to be maintained to enable colonization and ensure bacterial survival in the niche. The aims of the present review are to provide a brief outline of meningococcal carriage, disease and burden to society. With this background, we discuss several bacterial strategies that may enable its survival in the human respiratory tract during colonization and in the blood during infection. We also examine several known meningococcal adhesion mechanisms and conclude with a section on the potential processes that may operate in vivo as meningococci progress from the respiratory niche through the blood to reach the central nervous system.

Citing Articles

Analytical Challenges in Novel Pentavalent Meningococcal Conjugate Vaccine (A, C, Y, W, X).

Sharma P, Kale S, Phugare S, Goel S, Gairola S Vaccines (Basel). 2024; 12(11).

PMID: 39591130 PMC: 11598276. DOI: 10.3390/vaccines12111227.


A Presentation of Neisseria meningitidis in a Patient Taking Adalimumab as Immunosuppressive Therapy for Hidradenitis Suppurativa.

Bolling J, Holley A, Rogers C Cureus. 2024; 16(9):e68628.

PMID: 39371773 PMC: 11451091. DOI: 10.7759/cureus.68628.


A review on current advancement in zebrafish models to study chronic inflammatory diseases and their therapeutic targets.

Balde A, Ramya C, Nazeer R Heliyon. 2024; 10(11):e31862.

PMID: 38867970 PMC: 11167310. DOI: 10.1016/j.heliyon.2024.e31862.


Interaction of carrier and disease isolates of MenB cc32 and MenW cc22 with epithelial cells of the nasopharyngeal barrier.

Peters S, Mohort K, Claus H, Stigloher C, Schubert-Unkmeir A Front Cell Infect Microbiol. 2024; 14:1389527.

PMID: 38756230 PMC: 11096551. DOI: 10.3389/fcimb.2024.1389527.


Enzyme mechanistic studies of NMA1982, a protein tyrosine phosphatase and potential virulence factor in Neisseria meningitidis.

Wu S, Coureuil M, Nassif X, Tautz L Sci Rep. 2023; 13(1):22015.

PMID: 38086986 PMC: 10716126. DOI: 10.1038/s41598-023-49561-9.


References
1.
Weiser J, Goldberg J, Pan N, Wilson L, Virji M . The phosphorylcholine epitope undergoes phase variation on a 43-kilodalton protein in Pseudomonas aeruginosa and on pili of Neisseria meningitidis and Neisseria gonorrhoeae. Infect Immun. 1998; 66(9):4263-7. PMC: 108514. DOI: 10.1128/IAI.66.9.4263-4267.1998. View

2.
Muenzner P, Rohde M, Kneitz S, Hauck C . CEACAM engagement by human pathogens enhances cell adhesion and counteracts bacteria-induced detachment of epithelial cells. J Cell Biol. 2005; 170(5):825-36. PMC: 2171332. DOI: 10.1083/jcb.200412151. View

3.
Fredriksen J, Rosenqvist E, Wedege E, Bryn K, Bjune G, Froholm L . Production, characterization and control of MenB-vaccine "Folkehelsa": an outer membrane vesicle vaccine against group B meningococcal disease. NIPH Ann. 1991; 14(2):67-79; discussion 79-80. View

4.
Merz A, So M, Sheetz M . Pilus retraction powers bacterial twitching motility. Nature. 2000; 407(6800):98-102. DOI: 10.1038/35024105. View

5.
Kahler C, Stephens D . Genetic basis for biosynthesis, structure, and function of meningococcal lipooligosaccharide (endotoxin). Crit Rev Microbiol. 1999; 24(4):281-334. DOI: 10.1080/10408419891294216. View